CN113227051A - 用于视网膜疾病的化合物 - Google Patents

用于视网膜疾病的化合物 Download PDF

Info

Publication number
CN113227051A
CN113227051A CN201980083959.7A CN201980083959A CN113227051A CN 113227051 A CN113227051 A CN 113227051A CN 201980083959 A CN201980083959 A CN 201980083959A CN 113227051 A CN113227051 A CN 113227051A
Authority
CN
China
Prior art keywords
compound
reaction
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980083959.7A
Other languages
English (en)
Other versions
CN113227051B (zh
Inventor
李鹏
李小林
罗志
贺海鹰
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN113227051A publication Critical patent/CN113227051A/zh
Application granted granted Critical
Publication of CN113227051B publication Critical patent/CN113227051B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

提供了一种醛结合剂，具体公开了式(II)所示化合物或药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201980083959.7A 2018-12-18 2019-12-18 用于视网膜疾病的化合物 Active CN113227051B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811550604 2018-12-18
CN2018115506048 2018-12-18
CN201911226373 2019-12-04
CN201911226373X 2019-12-04
PCT/CN2019/126178 WO2020125659A1 (zh) 2018-12-18 2019-12-18 用于视网膜疾病的化合物

Publications (2)

Publication Number Publication Date
CN113227051A true CN113227051A (zh) 2021-08-06
CN113227051B CN113227051B (zh) 2022-05-17

Family

ID=71102478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980083959.7A Active CN113227051B (zh) 2018-12-18 2019-12-18 用于视网膜疾病的化合物

Country Status (9)

Country Link
US (1) US11932617B2 (zh)
EP (1) EP3901138A4 (zh)
JP (1) JP7165270B2 (zh)
KR (1) KR102651579B1 (zh)
CN (1) CN113227051B (zh)
AU (1) AU2019409160B2 (zh)
CA (1) CA3123473C (zh)
MX (1) MX2021007140A (zh)
WO (1) WO2020125659A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174524A1 (en) * 2020-06-17 2023-06-08 Medshine Discovery Inc. Aminopyridine compound
US11753377B2 (en) 2020-06-17 2023-09-12 Zhuhai United Laboratories Co., Ltd. Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound
CN116406263A (zh) * 2020-09-28 2023-07-07 珠海联邦制药股份有限公司 吡啶苯基类化合物的晶型及其制备方法
WO2024109905A1 (zh) * 2022-11-26 2024-05-30 珠海联邦制药股份有限公司 一种含有吡啶苯基类化合物的眼用制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135867A (zh) * 2015-08-21 2018-06-08 奥尔德拉医疗公司 醛结合物和其用途
WO2019075136A1 (en) * 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3032609A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
DE102017118202A1 (de) 2017-05-15 2018-11-15 Epcos Ag Folienkondensator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135867A (zh) * 2015-08-21 2018-06-08 奥尔德拉医疗公司 醛结合物和其用途
WO2019075136A1 (en) * 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS

Also Published As

Publication number Publication date
JP2022515755A (ja) 2022-02-22
EP3901138A4 (en) 2022-10-05
CA3123473A1 (en) 2020-06-25
AU2019409160A1 (en) 2021-08-05
EP3901138A1 (en) 2021-10-27
KR102651579B1 (ko) 2024-03-26
US20220127243A1 (en) 2022-04-28
CA3123473C (en) 2023-10-03
US11932617B2 (en) 2024-03-19
KR20210104111A (ko) 2021-08-24
MX2021007140A (es) 2021-11-03
AU2019409160B2 (en) 2022-03-24
CN113227051B (zh) 2022-05-17
WO2020125659A1 (zh) 2020-06-25
JP7165270B2 (ja) 2022-11-02

Similar Documents

Publication Publication Date Title
CN113227051B (zh) 用于视网膜疾病的化合物
CN115697338B (zh) 甲基取代的苯并二噁唑类化合物及其应用
WO2021259331A1 (zh) 八元含n杂环类化合物
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
CN111433196A (zh) 新颖缓激肽b2受体拮抗剂及其用途
WO2021104488A1 (zh) 作为jak抑制剂的三并杂环类化合物及其应用
TW202317097A (zh) 戊二醯亞胺類化合物與其應用
WO2021244634A1 (zh) 咪唑并吡啶类化合物及其用途
WO2023280317A1 (zh) 苄氨基三并环类化合物及其应用
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
WO2021159372A1 (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
WO2021018044A1 (zh) 一种sglt2/dpp4抑制剂及其应用
JP7296017B2 (ja) ベンゾスルタムを含む化合物
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN115210230A (zh) 杂环类化合物
CN116249533A (zh) 一类肠道裂解型共药及其制备和用途
US20240217949A1 (en) Compound for use in retinal diseases
WO2022206924A1 (zh) 含氮三并环双功能化合物及其制备方法和应用
WO2023207991A1 (zh) 稠合喹唑啉类化合物及其应用
CN118619932A (zh) Gpr40激动剂及其制备方法和应用
CN114746421A (zh) 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN118234734A (zh) 嘧啶三并环衍生物及其在药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049693

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230724

Address after: No.2428 Anji Road, Sanzao Town, Jinwan District, Zhuhai City, Guangdong Province 519040

Patentee after: ZHUHAI UNITED LABORATORIES Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.

TR01 Transfer of patent right